Clinical development of gene edited tacrolimus-resistant Treg (FKBP12KO-Treg) to enable simultaneous immunosuppression and support of immune regulation
Ghazaleh Zarrinrad, Lisa-Marie Burkhardt, C. Beltran-Mestres, Silvina Romero‐Suárez, Dimitrios L. Wagner, Stephan Schlickeiser, Maik Stein, Désirée J. Wendering, Iván Juky Carrera Diaz de la Cebosa, Lukas Ehlen, Frederik Hamm, Gavin Kurgan, Pawel Durek, Frederik Heinrich, Anamika Giri, , Leila Amini
This paper develops gene-edited tacrolimus-resistant Treg cells (FKBP12KO-Treg) for clinical use in transplant recipients, showing they maintain immunoregulatory function while resisting tacrolimus.
Molecular Therapy Advances · Apr 9, 2026Peer-reviewedImmunology